MicroRNA-140 (miR-140) is one of the most widely investigated miRNAs in cell carcinogenesis and cancer development. Despite present proposals of employing miR-140 as a candidate biomarker for cancer prognosis, its effectiveness in predicting patient survival and clinicopathological outcome is still under debate. A systematic search for English literature using online databases was performed with pre-established criteria. Odds ratios (ORs) or hazard ratios (HRs) with 95% confidence intervals (CIs) were collected to delineate the correlation between miR-140 levels and cancer patient prognosis. For this meta-analysis, we selected 12 papers for analysis, involving 1386 participants. Based on our analysis, high levels of miR-140 were strongly correlated with enhanced patient overall survival (OS) (HR = 0.728, 95% CI = 0.601-0.882, P = 0.001). In addition, we also observed that elevated miR-140 levels significantly led to better OS in patients with cancers in different parts of the body like digestive system (HR = 0.675, 95% CI = 0.538-0.848, P = 0.001), digestive tract (HR = 0.709, 95% CI = 0.565-0.889, P = 0.003), and head and neck (HR = 0.603, 95% CI = 0.456-0.797, P < 0.001). Additionally, we verified that the low miR-140 levels was related to advanced TNM stage (OR = 0.420, 95% CI = 0.299-0.590, P < 0.001), worse histologic grade (OR = 0.410, 95% CI = 0.261-0.643, P < 0.001), and positive lymph node metastasis status (OR = 0.341, 95% CI = 0.144-0.807, P = 0.014). Taken together, our results suggest that elevated miR-140 levels can be employed as a favorable biomarker for cancer patient prognosis. This information can greatly benefit in the formation of an individualized therapeutic plan for the treatment of cancer patients.

中文翻译：

---

microRNA-140 在癌症患者中表达的预后和临床病理学重要性：荟萃分析

MicroRNA-140 (miR-140) 是细胞癌变和癌症发展中研究最广泛的 miRNA 之一。尽管目前提议使用 miR-140 作为癌症预后的候选生物标志物，但其在预测患者生存和临床病理结果方面的有效性仍存在争议。使用在线数据库系统地搜索英语文献是按照预先建立的标准进行的。收集了具有 95% 置信区间 (CI) 的优势比 (OR) 或风险比 (HR) 以描述 miR-140 水平与癌症患者预后之间的相关性。对于这项荟萃分析，我们选择了 12 篇论文进行分析，涉及 1386 名参与者。根据我们的分析，高水平的 miR-140 与提高的患者总生存期 (OS) 密切相关（HR = 0.728，95% CI = 0.601-0.882，P = 0.001）。此外，我们还观察到升高的 miR-140 水平显着导致消化系统等身体不同部位的癌症患者的 OS 更好（HR = 0.675，95% CI = 0.538-0.848，P = 0.001）、消化道（HR = 0.709，95% CI = 0.565-0.889，P = 0.003）和头颈部（HR = 0.603，95% CI = 0.456-0.797，P < 0.001）。此外，我们证实低 miR-140 水平与晚期 TNM 分期（OR = 0.420，95% CI = 0.299-0.590，P < 0.001）、更差的组织学分级（OR = 0.410，95% CI = 0.261-0.643 , P < 0.001) 和阳性淋巴结转移状态 (OR = 0.341, 95% CI = 0.144-0.807, P = 0.014)。总之，我们的结果表明升高的 miR-140 水平可以用作癌症患者预后的有利生物标志物。